American Scene Radio - The Money Show with Steve Crowley Live Interview With Cannabis Science President And CEO Dr. Robert Melamede, Ph.D. On Tuesday, June 28th 11:29 am Eastern Standard Time

Cannabis Science, Inc. (OTCBB: CBIS), a pioneering US biotech company developing pharmaceutical cannabis products, is pleased to announce that Cannabis Science President And CEO Dr. Robert Melamede Ph.D., will be interviewed on American Scene Radio - The Money Show with Steve Crowley Live on Tuesday, June 28^th 11:29 am Eastern Standard Time.

About Steve Crowley's American Scene Radio Program

America’s #1 Money-Talk Radio Program… they own and produce the most successful, national Money-talk Radio program in America. "Steve Crowley's American Scene" was launched from the Disney/MGM Radio Studios at the Walt Disney World Resort in June 1990. American Scene attracts a larger and larger radio audience every month from coast to coast.

Today, they bring in 3,000,000 listeners on their three-hour daily radio broadcasts through the Information Radio Network, and on the Internet worldwide. This is the primary destination for Steve Crowley's insights and advice in the financial world. Plus Steve interviews all the top experts, analysts, money managers and authors covering stocks, investments, business, the economy and trends, Small-Cap CEOs and much more. More than 200 Financial "Stars” are interviewed in constant rotation….from Steve Forbes, Tobin Smith, Beth Dater, Larry Kudlow plus many more. No other Money-talk Radio Program in America even comes close to this level of credible content. Plus they broadcast LIVE from all the Money Shows around the country.

All shows are produced with an entertaining flair that translates into unique, interactive talk radio. Please click here to LISTEN LIVE to these programs Mon-Fri from 10am-12noon (EST) and 7am-9am (PST); and 1pm - 2pm (EST) and 10am-11am (PST) Mon-Fri.

Listeners can tune in at; http://americansceneradio.com/ to hear the live interview.

Dr. Melamede will be discussing several topics about Cannabis Science including:

Cannabis Science has a licensed dispensary, Rockbrook Inc. that is located in Denver, Colorado. Our formulations to treat cancer and other ailments are available through this dispensary along with others as we expand licensing agreements in Colorado and other legal medical marijuana states, as regulations permit. We are currently in negotiations with other Colorado dispensaries in addition to deals in other states that will we announce as soon as negotiations progress further. Our medicine will become available in these other dispensaries as deals are finalized.

To expand our international market we are focusing on independent first nations, Thailand, Europe, and the Philippines as well as other markets depending on regulatory approval and conditions and these market areas. The Thailand in particular may be well suited for a Cannabis Science treatment resort where patients would receive our branded medicine.

The critical ailments we target are: cancer first (basal cell carcinoma topical) contains THC but not ingested, applied topically so no one gets high, and glioma where the patient will orally consume the preparation), then PTSD and chronic pain.

We are primarily focused on raising capital to take our formulations through the FDA for approval, similar to GW Pharmaceuticals so our products are available on a national scale. In conjunction with the planned FDA submissions for our formulations, we are involved with a number of patients self-administering cannabis extracts for cancer treatment and continue to use patient testimonials and evidence to support the efficacy of our medicine.

Despite regulatory challenges we see continued growth for the estimated $1.7 billion industry and Cannabis Science will continue to build its dispensary base that will drive growth and revenues for our company. Support is much needed at this juncture to help us make our medicine more broadly available to treat cancer and other ailments.

We are also advocating for federal legalization of medical marijuana so patients don’t have to live in fear of federal prosecution, despite following state law. We support several organizations such as NORML, MPP, (etc) to help bring about legalization.

Dr. Robert J. Melamede, the CEO and President of Cannabis Science Inc., stated, "We are thankful to Steve Crowley and American Scene Radio for giving us this opportunity to share what Cannabis Science is about and the incredible treatment results that patients are seeing with our medical marijuana formulations. We are on the verge of a revolution in medicine and Cannabis Science is at the forefront of this movement; bringing cannabis into modern medicine.”

About Cannabis Science, Inc.

Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Forward Looking Statements; This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.